mynth
10/2020100%

Haselmeier acquired by Sulzer

SWITZERLAND Life Sciences / Medical Devices / Medical Consumables EV €100–350M

Context

Sulzer has completed the acquisition of Haselmeier, integrating the drug delivery specialist into its Applicator Systems (APS) division. The transaction was structured to acquire 100% of the privately held Swiss-German company, allowing Sulzer to immediately scale its healthcare business and leverage Haselmeier’s significant portfolio of proprietary intellectual property.The strategic rationale for this acquisition is centered on technical synergy and market expansion. By combining Haselmeier’s competence in self-injection devices with Sulzer’s existing expertise in precision injection molding and liquid mixing, the group intends to accelerate the development of innovative and differentiated medical devices. This move allows Sulzer to pivot its APS division toward the high-growth pharmaceutical market, particularly in indications requiring frequent subcutaneous injections. The integration is expected to yield substantial cost synergies through the insourcing of manufacturing processes and the utilization of Sulzer’s global industrial infrastructure.

Haselmeier, which reported an EBITDA margin of [members only] in 2019, is valued in this transaction at an EV/EBITDA multiple of 15x–25x.

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in the 20th century, Haselmeier is a leading Swiss-German developer and manufacturer of innovative drug delivery systems, specializing in subcutaneous self-injection devices. The company operates a high-value business model centered on proprietary intellectual property (IP), providing customized solutions such as injection pens for fast-growing medical indications including diabetes, reproductive health, growth disorders, and osteoporosis. Its value proposition lies in its end-to-end service offering, covering the entire product lifecycle from initial design, prototyping, and engineering to industrial-scale production in modern manufacturing facilities. Haselmeier’s strategy emphasizes being a reliable development partner for pharmaceutical companies, offering additional services such as lifecycle management, pharmaceutical packaging, and regulatory support. By focusing on patented platform technologies for injection devices, the company ensures the safe and precise self-administration of liquid drugs, catering to the increasing global demand for home-based healthcare and patient-centric delivery solutions.

Ent. Value

€100–350M

Equity Value

[members only]

Multiples

EV / Revenue

2x–6x

EV / EBITDA

15x–25x

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2019
€25–50M
€5–25M
[members only]
2018
€25–50M
€5–25M
[members only]

Other operations with Sulzer

Other operations with Sulzer
DateAcquirerTargetCountrySector
02/2021SULZERNORDIC WATERSWEDENValves, Pumps & Taps

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
01/2021SAGARDNUTRISENSFRANCENutrition & Dietary Supplements
11/2020NOVALPINA CAPITALLABORATOIRE X.OFRANCEGenerics / Labs
10/2020ARDIANH2 PHARMAFRANCECDMO
09/2020EQT PARTNERSSCHÜLKEGERMANYMedical Consumables
09/2020PATRICIA INDUSTRIESADVANCED INSTRUMENTSUNITED STATESDiagnostic Equipment
09/2020NESTLEIM HEALTHSCIENCEUNITED STATESNutrition & Dietary Supplements
09/2020PERMIRANEURAXPHARMGERMANYGenerics / Labs
06/2020AVISTA CAPITAL PARTNERSVISION HEALTHCAREBELGIUMNutrition & Dietary Supplements
04/2020ROYAL DSMGLYCOMDENMARKNutrition & Dietary Supplements
04/2020AMERICAN SECURITIESPARAGON MEDICALUNITED STATESMedical Devices

REFERENCES

Valuation range: EV €100–350M

Revenue range: €25–50M

EBITDA range: €5–25M

EV/Revenue range: 2x - 6x

EV/EBITDA range: 15x - 25x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Haselmeier by Sulzer are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

FAQ

What transaction does this page cover?

This page covers Sulzer’s acquisition of 100% of Haselmeier, a Swiss company specialised in Medical Devices, in 2020.

How was the acquisition of Haselmeier by Sulzer valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €100–350M band, its EV/EBITDA multiple within the 15x - 25x range, and its EV/revenue multiple within the 2x - 6x range. Exact figures are available to members.

What were Haselmeier’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Haselmeier generated annual revenue estimated in the €25–50M range and EBITDA in the €5–25M bracket (FY 2019). Detailed financial figures are available to members.

What sources support the information on this transaction?

Information on this transaction is sourced from the official corporate announcement published by the parties, corroborated by a private document shared by the community and verified by the mynth team to ensure the accuracy of the shared information.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.